#1 Clinical Trials Search in Europe

Elexacaftor

Elexacaftor, a groundbreaking drug used in combination therapy for cystic fibrosis (CF), has shown promising results in various clinical trials. This article explores the impact of elexacaftor-based treatments on different aspects of CF, including lung function, gastrointestinal issues, and overall quality of life for patients across different age groups.

Table of Contents

What is ELEXACAFTOR?

ELEXACAFTOR is a groundbreaking medication used in the treatment of cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. It is often used in combination with two other drugs, tezacaftor and ivacaftor, forming a triple therapy known as ETI[1]. This combination is also known by brand names such as Kaftrio[2] or Trikafta[5].

How Does ELEXACAFTOR Work?

ELEXACAFTOR belongs to a class of drugs called CFTR modulators. CFTR stands for Cystic Fibrosis Transmembrane Conductance Regulator, which is a protein that is faulty in people with CF. ELEXACAFTOR works by helping the CFTR protein function better, which can improve symptoms of CF[1].

Specifically, ELEXACAFTOR is a CFTR corrector. It helps the CFTR protein fold correctly and move to the cell surface where it can function properly. When combined with tezacaftor (another corrector) and ivacaftor (a potentiator that helps the CFTR channel stay open longer), it forms a powerful treatment that significantly improves CFTR function[1].

Who Can Use ELEXACAFTOR?

ELEXACAFTOR, as part of the triple combination therapy, is approved for use in patients with CF who:

  • Are 6 years of age or older[2]
  • Have at least one copy of the F508del mutation in the CFTR gene[1]

The F508del mutation is the most common CF-causing mutation. However, eligibility for this treatment should always be determined by a healthcare provider based on a patient’s specific genetic profile and overall health status[5].

Benefits of ELEXACAFTOR

Research has shown that ELEXACAFTOR, as part of the triple combination therapy, can provide significant benefits for people with CF:

  • Improved lung function: Studies have shown substantial increases in FEV1 (a measure of how much air a person can exhale in one second)[1]
  • Reduced pulmonary exacerbations: Fewer episodes of worsening respiratory symptoms[1]
  • Better quality of life: Patients report improvements in respiratory symptoms and overall well-being[1]
  • Potential improvements in other CF-related issues: Some studies are investigating effects on sinus disease, glucose tolerance, and growth in children[3][4][5]

Ongoing Research

Several studies are currently underway to further understand the effects of ELEXACAFTOR:

  • Impact on sinus disease: Researchers are investigating how ELEXACAFTOR affects chronic rhinosinusitis (inflammation of the sinuses) and sense of smell in CF patients[6]
  • Effects on glucose tolerance: A study is looking at how ELEXACAFTOR might improve glucose tolerance and potentially reduce the risk of CF-related diabetes[3]
  • Long-term effects in children: The BEGIN study is examining how ELEXACAFTOR impacts growth, gut health, lung function, and other aspects of CF in young children over several years[5]
  • Impact on liver and gut health: Some studies are using advanced imaging techniques to see how ELEXACAFTOR affects the liver and intestines in CF patients[2]

Side Effects and Monitoring

While ELEXACAFTOR has shown significant benefits, like all medications, it can have side effects. Common side effects may include headache, upper respiratory tract infections, stomach pain, diarrhea, rash, and increased liver enzymes[7].

When starting ELEXACAFTOR, patients are typically closely monitored. This may include:

  • Regular lung function tests (spirometry)[7]
  • Blood tests to check liver function[7]
  • Monitoring of respiratory symptoms[7]
  • In some cases, more advanced tests like sinus MRI scans or glucose tolerance tests[3][6]

It’s important for patients to communicate regularly with their healthcare team about any changes in symptoms or new side effects they experience while taking ELEXACAFTOR[7].

Aspect Findings
Lung Function Significant improvements in FEV1 and reduction in pulmonary exacerbations
Gastrointestinal Function Potential improvements in small bowel water content and liver function
Sinus Disease Reduction in sinus opacification and improvement in olfactory function
Glucose Tolerance Possible positive effects on glucose metabolism and insulin needs
Growth in Children Studies ongoing to assess impact on growth factors and height
Quality of Life Improvements reported in various quality of life measures
Age Groups Initially approved for 12+ years, studies ongoing in younger children
Long-term Effects Studies planned for up to 10 years to assess long-term impacts

FAQ

  • What is elexacaftor and how does it work in treating cystic fibrosis? Elexacaftor is part of a triple combination therapy (along with tezacaftor and ivacaftor) that helps improve the function of the defective CFTR protein in cystic fibrosis. It works by increasing the availability and opening probability of CFTR channels at cell membranes, which helps improve mucus clearance and organ function in CF patients.
  • What are the main benefits observed in clinical trials using elexacaftor? Clinical trials have shown that elexacaftor-based treatments can significantly improve lung function, reduce pulmonary exacerbations, and potentially impact other aspects of CF such as gastrointestinal function, glucose tolerance, and sinus disease. Some trials have reported improvements in FEV1 (a measure of lung function) and quality of life scores.
  • Are there any age restrictions for using elexacaftor in CF treatment? While initial approvals were for patients 12 years and older, recent clinical trials are exploring the use of elexacaftor-based treatments in younger age groups, including children aged 6-11 years. Some studies are even investigating its effects on infants and young children to understand the potential benefits of early intervention.
  • What are some of the areas being studied besides lung function in elexacaftor trials? Clinical trials are investigating the effects of elexacaftor on various aspects of CF, including sinus disease, olfactory function, gastrointestinal issues, glucose tolerance, growth factors in children, liver function, and bone health. These studies aim to provide a comprehensive understanding of how the treatment impacts overall health in CF patients.
  • How long do clinical trials typically monitor patients on elexacaftor treatment? The duration of monitoring in clinical trials varies, but many studies follow patients for at least 6 months to 1 year after starting treatment. Some long-term studies, like the BEGIN study, plan to monitor patients for up to 5-10 years to assess the long-term effects of the treatment on growth and other health parameters in children with CF.

Ongoing Clinical Trials on Elexacaftor

  • Study of VX-121, Tezacaftor, and Deutivacaftor for Children Aged 1-11 with Cystic Fibrosis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

    Not yet recruiting

    1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Ireland +5

  • Study of elexacaftor, tezacaftor and ivacaftor combination therapy to evaluate blood levels in patients with Cystic Fibrosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor in Children and Adults with Cystic Fibrosis Aged 2 Years and Older

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands

  • Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +7

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor for Cystic Fibrosis in Patients Aged 12 Months and Older

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany The Netherlands

Glossary

  • CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, a protein that is defective in people with cystic fibrosis, leading to thick, sticky mucus in various organs.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that indicates how much air a person can exhale in one second.
  • Pulmonary exacerbation: A worsening of respiratory symptoms in cystic fibrosis patients, often requiring additional treatment or hospitalization.
  • Elexacaftor: A medication used in combination with tezacaftor and ivacaftor to treat cystic fibrosis by improving CFTR protein function.
  • Tezacaftor: A CFTR corrector medication used in combination therapy for cystic fibrosis.
  • Ivacaftor: A CFTR potentiator medication that helps increase the opening of CFTR channels in cystic fibrosis treatment.
  • Chronic rhinosinusitis: Long-term inflammation of the nasal passages and sinuses, a common complication in cystic fibrosis.
  • Olfactory dysfunction: Impairment in the sense of smell, which can occur in cystic fibrosis patients due to sinus disease.
  • Glucose tolerance: The body's ability to process and manage blood sugar levels, which can be affected in cystic fibrosis patients.
  • Sweat chloride test: A diagnostic test for cystic fibrosis that measures the amount of chloride in a person's sweat.

References

  1. https://clinicaltrials.gov/study/NCT05576324
  2. https://clinicaltrials.gov/study/NCT05699148
  3. https://clinicaltrials.gov/study/NCT06331000
  4. https://clinicaltrials.gov/study/NCT04056702
  5. https://clinicaltrials.gov/study/NCT04509050
  6. https://clinicaltrials.gov/study/NCT06191640
  7. https://clinicaltrials.gov/study/NCT05599230